Clinically, these pathways could represent actionable vulnerabilities; targeting IQGAP1 or its interaction networks [32] might offer novel therapeutic strategies for PALB2-mutated breast cancers, particularly those resistant to conventional DNA repair-targeted treatments [33]. This evidence concerns the gene IQGAP1 and breast cancer.